NIH trial: mobile units with PrEP and opioid care cut deaths 71% among people who inject drugs
The five-city HPTN 094 trial found no difference in PrEP or opioid-treatment uptake between arms, and NIH says the result needs replication.
Key takeaways
- An NIH release dated November 4, 2026 reports that mobile units delivering integrated HIV prevention and addiction care reduced all-cause deaths by 71% compared with peer navigation to fixed community services.
- The HPTN 094 trial enrolled 409 adults without HIV who injected drugs and had opioid use disorder in Houston, Los Angeles, New York City, Philadelphia and Washington, D.C.
- Investigators found no difference between arms in use of daily oral PrEP or medication for opioid use disorder; 14% of participants were on MOUD at 26 and 52 weeks.
- Mortality was a secondary outcome, and NIH says the finding needs replication before it can be treated as settled.
- For crews: the release does not report causes of death, overdose counts or any EMS-specific data from the five study cities.
A National Institutes of Health (NIH) news release dated Wednesday, November 4, 2026, reports that a randomized trial in five large US cities found fewer deaths among people who inject drugs when HIV prevention and addiction treatment were delivered together from mobile medical units [1]. According to the release, participants assigned to the mobile units had 71% fewer all-cause deaths than participants who received peer navigation to existing community services [1].
The trial, HIV Prevention Trials Network Study 094 (HPTN 094), was funded by NIH's National Institute on Drug Abuse (NIDA) and run in Houston, Los Angeles, New York City, Philadelphia, and Washington, D.C. [1]. The results were published in JAMA Psychiatry, with Steven Shoptaw of UCLA and Nabila El-Bassel of Columbia University listed as the lead authors and study co-chairs [1].
NIH frames the mortality result cautiously. The release states that the trial "shows mobile units may help overcome significant barriers to accessing HIV and addiction treatment, but replication is needed" [1]. The reduction in deaths was a secondary outcome, and the primary measures of medication use did not differ between the two arms [1].
What the records show
According to the NIH release, HPTN 094 enrolled 409 adults who did not have HIV, injected drugs, had opioid use disorder, were not on medication for opioid use disorder (MOUD) at enrollment, and were willing to consider starting it [1].
Participants were split into two groups [1]:
- Mobile unit arm: 26 weeks of peer navigation plus integrated preexposure prophylaxis (PrEP), MOUD, and limited clinical and supportive services delivered on a mobile unit [1].
- Comparison arm: 26 weeks of peer navigation that linked participants to available non-mobile community services [1].
On the planned medication outcomes, NIH reports no difference between the arms in use of daily oral PrEP or MOUD [1]. Verified PrEP use was low in both groups at 26 weeks, although the release describes it as favorable compared with self-reported PrEP use among people who inject drugs generally [1]. Across the study, 14% of participants were using MOUD at 26 and 52 weeks [1]. The release calls that figure "a clinically meaningful level considering none were on MOUD at study start" [1].
The mortality finding is described as a secondary outcome that reached statistical significance, with a 71% reduction in all-cause deaths in the mobile unit arm relative to the comparison arm [1]. The release does not give the number of deaths in either group.
NIDA director Nora D. Volkow said in the release that "these findings suggest that delivering low threshold services through mobile units could save lives" [1]. El-Bassel said people who inject drugs "often face fragmented systems, unstable housing, stigma, and other barriers that make sustained care difficult" [1].
The HIV Prevention Trials Network is sponsored by NIH's National Institute of Allergy and Infectious Diseases, and HPTN 094 was funded by NIDA under awards UM1AI068619, UM1AI068617, and UM1AI068613 [1].
Why it matters for clinicians
The population studied overlaps heavily with the patients EMS, emergency departments and public-health outreach teams encounter on overdose, infection and welfare calls [1]. Volkow's statement in the release describes injection drug use as "an important contributor to HIV in the U. S. that also increases risk for other serious infectious diseases" [1].
The trial tested a service model rather than a new drug. Both arms received peer navigation, so the difference being measured was whether co-locating PrEP, MOUD and basic clinical and supportive care on a vehicle changed outcomes compared with referral to fixed-site services [1]. The release reports that it changed survival but not medication uptake, which leaves the mechanism of the mortality benefit unexplained in the record [1].
The investigators also draw a conclusion about PrEP. According to the release, the low oral PrEP use even with structured peer navigation shows that acceptance of PrEP remains a major challenge among people who inject drugs, and the researchers point to evaluating long-acting PrEP formulations in this population [1]. The release does not say how the HPTN 094 units compare with mobile health programs already operating in US cities.
What the records do not tell us
- Causes of death are not reported. The release gives a relative reduction in all-cause mortality but no breakdown by overdose, infection or other cause, and no raw counts [1].
- No per-city results. The release names the five cities but does not report outcomes separately for any of them [1].
- No detail on the units or staffing. The release describes "limited clinical and supportive services" on the mobile unit but does not specify what was offered, who staffed it, or how often participants visited [1].
- Mechanism unexplained. Because PrEP and MOUD use did not differ between arms, the release does not explain what drove the lower death rate [1].
- Secondary outcome. NIH states that replication is needed, and the mortality result was not the trial's primary endpoint [1].
- Full study details. The JAMA Psychiatry paper (DOI 10.1001/jamapsychiatry.2026.3644) is referenced in the release but its contents, including confidence intervals and follow-up length for mortality, are not in the record reviewed here [1].
What to watch
The release points to evaluation of long-acting PrEP formulations among people who inject drugs as the next research question raised by the trial [1]. It does not name a follow-on study or date. NIH also says the mortality finding requires replication, but the record does not identify a planned replication trial [1].
Questions readers ask
What did the HPTN 094 trial find?
According to a November 4, 2026 NIH release, people who inject drugs who received integrated PrEP, opioid use disorder medication and supportive services on a mobile unit had 71% fewer all-cause deaths than those referred to community services through peer navigation. There was no difference between groups in PrEP or MOUD use.
Where was the HPTN 094 mobile unit trial conducted?
The trial took place in Houston, Los Angeles, New York City, Philadelphia, and Washington, D.C., and enrolled 409 adults without HIV who injected drugs and had opioid use disorder.
Did mobile units increase PrEP or MOUD use in the trial?
No. NIH reports no difference between study arms in use of daily oral PrEP or medication for opioid use disorder. Verified PrEP use was low in both arms, and 14% of participants were on MOUD at 26 and 52 weeks.
Who funded and published the HPTN 094 study?
The study was funded by NIH's National Institute on Drug Abuse and published in JAMA Psychiatry in 2026, with Steven Shoptaw and Nabila El-Bassel as study co-chairs. NIH says the mortality finding needs replication.
Sources
- NIH news release: Integrated health service delivery through medical mobile units helped to reduce deaths among individuals at risk for HIV who also inject drugs (Nov. 4, 2026) — nih.gov. nih.gov/news-events/news-releases/integrated-health-service-delivery-t
This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.
